Cullinan files NDA for zipalertinib in first-line EGFR ex20ins NSCLC

Cullinan Therapeutics has initiated a New Drug Application submission to the US Food and Drug Administration for zipalertinib in combination with platinum-based chemotherapy, targeting previously untreated locally advanced or metastatic non-small cell lung cancer harbouring EGFR exon 20 insertion mutations. The submission is proceeding under the FDA's Real-Time Oncology Review programme, which allows sponsors to submit clinical data in advance of the complete package to enable earlier efficacy and safety review. Full NDA submission is expected by the end of 2026.

The application draws on data from the Phase 3 REZILIENT3 trial, which met its primary endpoint of progression-free survival. The company reported a statistically significant and clinically meaningful improvement in median PFS for the combination versus chemotherapy alone, which it described as the longest median PFS observed to date in this first-line setting. Results were presented at a Presidential Symposium at the IASLC 2026 World Conference on Lung Cancer, a high-profile platform typically reserved for potentially practice-changing datasets.

Regulatory context

Zipalertinib already holds FDA Breakthrough Therapy designation in the second-line EGFR ex20ins NSCLC setting, and a separate NDA seeking accelerated approval for zipalertinib monotherapy in that indication is currently under review with a PDUFA target action date of 27 February 2027. The first-line combination filing therefore opens a second, broader regulatory front that could materially expand the drug's commercial footprint if approved.

Cullinan is eligible to receive milestone payments of $30 million on second-line US approval and $100 million on first-line approval under its collaboration with Taiho Oncology and its parent Taiho Pharmaceutical, which co-develop zipalertinib. The drug is an orally available, irreversible EGFR inhibitor designed specifically to inhibit exon 20 insertion variants, a subset historically poorly served by earlier-generation EGFR inhibitors such as erlotinib and gefitinib.

Market landscape

EGFR exon 20 insertion mutations account for approximately 4% of all NSCLC cases globally and up to 12% of EGFR-mutant NSCLC in the United States, representing a population of several thousand new patients annually. The indication has attracted growing competitive interest. Amivantamab, marketed by Johnson and Johnson as Rybrevant, holds approval in the second-line ex20ins setting and has reported first-line data in combination with chemotherapy, making it the most directly comparable approved therapy. Mobocertinib, which had received accelerated approval in the same setting, was voluntarily withdrawn from the US market in 2023 following a negative Phase 3 readout, illustrating the regulatory and clinical bar that confirmatory trials must clear.

A successful first-line approval for zipalertinib would position Cullinan and Taiho to compete directly with amivantamab-based regimens at the point of diagnosis, where treatment decisions typically carry the greatest commercial weight. Investors will now focus on whether the RTOR process accelerates a priority review timeline and whether Cullinan chooses to pursue a supplemental filing in ex-US markets through Taiho's broader network.